Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Capacity of human subjects to utilize keto analogues of valine and phenylalanine
Daniel Rudman
Daniel Rudman
Published January 1, 1971
Citation Information: J Clin Invest. 1971;50(1):90-96. https://doi.org/10.1172/JCI106488.
View: Text | PDF
Research Article

Capacity of human subjects to utilize keto analogues of valine and phenylalanine

  • Text
  • PDF
Abstract

Three adult human subjects were maintained for 7 days (period I) on a protein-free formula diet containing the minimum daily requirements of the eight essential amino acids plus 40 g glycine. During the last 5 days of this period, the average daily nitrogen balances for the three subjects were +0.52, +0.71, and +0.30 g, respectively. During the next 7 days (period II), valine was withdrawn from the diet, and the glycine ration increased by an equimolar amount. During the last 5 days of period II, average daily nitrogen balances declined to -1.82, -1.61, and -1.87 g, respectively. In the final period of 7 days (period III), the keto analogue of valine, α-ketoisovaleric acid, was added to the diet in a quantity equimolar to the minimum daily requirement of valine. During the last 5 days of this period, average daily nitrogen balances improved to -0.02, -0.18, and -0.83 g, respectively. Analogous experiments in three subjects involved the withdrawal from the diet of phenylalanine (period II) and replacement by its keto analogue, phenylpyruvic acid (period III). The average daily nitrogen balances were as follows: period I: +1.04, +0.96, and +0.53 g; period II: -1.45, -1.83, and -1.94 g; period III: +0.07, +0.11, and -0.52 g.

Authors

Daniel Rudman

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts